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Abstract
Furan, a possible human carcinogen, is found in heat treated foods and tobacco smoke. Previous 
studies have shown that humans are capable of converting furan to its reactive metabolite, cis-2-
butene-1,4-dial (BDA), and therefore may be susceptible to furan toxicity. Human risk assessment 
of furan exposure has been stymied because of the lack of mechanism-based exposure biomarkers. 
Therefore, a sensitive LC-MS/MS assay for six furan metabolites was applied to measure their 
levels in urine from furan-exposed rodents as well as in human urine from smokers and 
nonsmokers. The metabolites that result from direct reaction of BDA with lysine (BDA-Nα-
acetyllysine) and from cysteine-BDA-lysine cross-links (N-acetylcysteine-BDA-lysine, N-
acetylcysteine-BDA-Nα-acetyllysine and their sulfoxides) were targeted in this study. Five of the 
six metabolites were identified in urine from rodents treated with furan by gavage. BDA-Nα-
acetyllysine, N-acetylcysteine-BDA-lysine and its sulfoxide were detected in most human urine 
samples from three different groups. The levels of N-acetylcysteine-BDA-lysine sulfoxide were 
more than 10 times higher than the corresponding sulfide in many samples. The amount of this 
metabolite was higher in smokers relative to non-smokers and was significantly reduced following 
smoking cessation. Our results indicate a strong relationship between BDA-derived metabolites 
and smoking. Future studies will determine if levels of these biomarkers are associated with 
adverse health effects in humans.
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Introduction
cis-2-Butene-1,4-dial (BDA) is a toxic metabolite of the liver toxicant and carcinogen, 
furan.1 Metabolites detected in the urine of furan-treated rats are primarily derived from the 
reaction of BDA with cellular nucleophiles such as lysine and cysteine (Scheme 1).2–6 
Abundant metabolites include the reaction product between lysine and BDA, L-2-
(acetylamino)-6-(2,5-dihydro-2-oxo-1H-pyrrol-1-yl)hexanoic acid (1), and downstream 
metabolites of cysteine-BDA-lysine cross-links, N-acetyl-S-[1-(5-amino-5-
carboxylpentyl)-1H-pyrrol-3-yl]-L-cysteine (2) and its sulfoxide (3) as well as the N-
acetyllysine derivatives of these compounds (4 and 5, respectively). These metabolites are 
likely degradation products of adducted proteins since approximately 13% of a 8 mg/kg dose 
of furan becomes covalently bound to liver proteins.7 Therefore, these urinary metabolites 
represent not only biomarkers of furan metabolism to BDA but also potential biomarkers of 
furan-derived toxicity.
The human health effects of this potent liver toxicant and carcinogen are not known. 
Therefore, development of biomarkers of furan metabolism and toxicity for human studies is 
warranted. Humans are exposed to furan through processed food, pollution, car exhaust and 
cigarette smoke.8,9 The contribution of canned and processed foods to furan exposure is 
estimated to be 0.3 μg/kg/day.10,11 Smokers may be exposed to much larger amounts of 
furan than non-smokers since cigarette smoke contains significant levels of furan (20 – 40 
μg/cigarette, depending on the method of analysis).12–14 Therefore, furan could be a 
significant contributor to the adverse health effects associated with tobacco smoke. To 
address this question, a sensitive LC-MS/MS assay was developed to quantify the levels of 
BDA-derived metabolites in urine. This assay was then used to determine levels of these 
metabolites in nonsmokers and smokers at baseline and following smoking cessation.
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[2H6]Acetic anhydride was purchased from Cambridge Isotope Laboratories, Inc (Andover, 
MA). Standards for metabolites 1, [13C615N2]1, 2, [13C615N2]2, 4 and [13C615N2]4, 5, and 
[13C615N2]5, were prepared as previously published.3,15,16 Concentrations of the standards 
in [2H6]DMSO was determined by quantitative NMR analysis as previously described.16,17 
All other chemicals were purchased from Fisher Scientific (Fairlawn, NJ).
Animal Studies
All animal studies were approved by the University of Minnesota Institutional Animal Care 
and Use Committee. Female B6C3F1 mice (18–20 g) and male F344 rats (200–300 g) were 
purchased from Charles River Laboratories (Kingston, NY). F344 rats and B6C3F1 mice 
were selected for these studies because they have been used to assess furan toxicity in 
numerous short and long term studies.18–22 Male and female B6C3F1 mice have similar 
biochemical, proliferative and toxic responses to the hepatic effects of furan.19,21 Female 
mice were used because previous in vivo studies were carried out in this fashion.23 Male rats 
are more sensitive to the hepatocellular carcinogenic properties of furan.18 For this reason, 
all our metabolism studies have been performed in male F344 rats.2–5
Two groups of five mice received 0 or 8 mg/kg furan (n = 5) in 5 mL/kg corn oil by gavage. 
Immediately after treatment, mice were transferred to metabolism cages in groups of five. 
The pooled urine was collected on dry ice over 24 hours. Male F344 rats were given 0, 8 or 
40 mg/kg furan in 5 mL corn oil by gavage as previously described.3 Rats were immediately 
transferred to metabolism cages after treatment. Urine was collected on dry ice for 24 hours.
Human urine samples
Urine from human nonsmokers (n = 15; 12 female and 3 males) was provided by the 
University of Minnesota Masonic Cancer Center Tobacco Biorepository. Urine from 
smokers at baseline (day 0) and up to 84 days after smoking cessation (n = 16; 11 females 
and 5 males) was collected as part of the Persistence of Biomarkers (POB) study conducted 
at the University of Minnesota.24 Additionally, urine samples from non-smokers and 
smokers were obtained from the Shanghai (all males) and Singapore (5 males and 5 females) 
cohort studies (five non-smokers and five smokers from each cohort).25,26 The Singapore 
samples were previously treated with ascorbic acid (0.4 g/20 mL urine). Pooled smoker 
urine provided by the laboratory of Stephen Hecht was employed for assay quality control. 
All urine had been stored at −20° C. Creatinine in the urine samples was measured using a 
colorimetric microplate assay (CRE34-K01) purchased from Eagle Bioscience (Nashua, 
NH). Cotinine, a measure of nicotine intake, was measured in the baseline POB study 
samples using an established GC-MS method.27
Urine sample preparation
[13C615N2]Labeled internal standards (5 pmol for metabolites 1, 2, 5 and 2.5 pmol for 
metabolite 4) were added to 20 (rodent), 100 (Shanghai/Singapore) or 250 (POB) μL of 
urine in a 1.5 mL microcentrifuge tube. The urine was brought to a final volume of 1 mL by 
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the addition of a corresponding volume of 500 mM sodium bicarbonate (POB study 
samples) or 750 mM sodium bicarbonate (rodent and Shanghai and Singapore cohort 
samples) prior to the addition of [2H6]acetic anhydride (25 μL). Tubes were briefly inverted 
to mix and then immediately uncapped. After 45 min at room temperature, these acetylated 
urine samples were applied to Oasis MAX cartridges (60 mg, Waters, Milford, MA) after the 
cartridges had been conditioned with 2 mL each of methanol and 2% (v/v) ammonium 
hydroxide. Furan metabolites were eluted from the cartridge with 1% (v/v) formic acid 
containing 40% (v/v) methanol (1, 6 as [2H3]1, [13C615N2]1, 5, 3 as [2H3]5, and 
[13C615N2]5) and 100% methanol (4, [2H3]4, [13C615N2]4 and [13C615N2]2 as 
[13C62H315N2]4). Fractions were collected in the presence of 15 mM ammonium acetate 
(200 μL) in glass vials. The organic solvent was immediately removed under reduced 
pressure. Following acidification with 500 μL of 1% (v/v) formic acid, the fractions were 
individually applied to Sep-Pak® Vac 18 cartridges (50 mg, Waters) that were 
preconditioned with 2 mL each methanol and water. Metabolites were eluted with 1 mL each 
15% (v/v) (1, 6 as [2H3]1, [13C615N2]1, 5, 3 as [2H3]5, and [13C615N2]5) and 30% (v/v) 
methanol (4, 2 as [2H3]4, [13C615N2]4, and [13C615N2]2 as [13C62H315N2]4). Eluents were 
collected in the presence of 15 mM ammonium acetate (200 μL) in glass vials, then 
immediately concentrated to dryness under reduced pressure. Samples were stored at −80° C 
until analysis.
LC-MS/MS analysis
Samples were reconstituted in 100 μL of 15 mM ammonium acetate containing 1% (v/v) 
methanol for LC-MS/MS analysis. Levels of furan metabolites were measured on a Thermo 
Scientific TSQ Vantage mass spectrometer attached to an Eksigent nanoLC-ultra 2D pump 
and autosampler system using established selected reaction monitoring parameters for these 
metabolites.16,17 The mixtures (8 μL) were separated on a Phenomenex Synergi Hydro-RP 
column (250 mm × 0.5 mm, 80 Å pore size 4 μm) eluting with 15 mM ammonium acetate 
(solvent A) with a methanol (solvent B) gradient at a flow rate of 10 μL/min. Initial 
conditions were 99% A, 1% B. After 3.5 min, the gradient was linearly increased to 20% B 
over 17.5 min, then increased to 70% B over 5 min. After 2 min, the column was returned to 
initial conditions in 2 min. The electrospray ionization source was operated in negative ion 
mode. Source spray voltage was 3000 V. Nitrogen sheath gas pressure was 35. Q2 argon gas 
pressure was 1 mTorr. Declustering voltage was −5 V. Transitions monitored were as 
follows: 1, m/z 253 → m/z 211; 6 as [2H3]1, m/z 256 → m/z 212; [13C615N2]1, m/z 261 → 
m/z 219; 4, m/z 398 → m/z 269; 2 as [2H3]4, m/z 401 → m/z 272; [13C615N2]4, m/z 406 
→ m/z 277; [13C615N2]2 as [2H313C615N2]4, m/z 409 → m/z 280; 5, m/z 414 → m/z 285; 
3 as [2H3]5, m/z 417 → 288; and [13C615N2]5, m/z 422 → m/z 293. A small subset of 
samples were analyzed for multiple fragments of [2H3]4 (m/z 401 → m/z 272, m/z 228 and 
m/z 98) and [2H313C615N2]4 (m/z 409 → m/z 280, m/z 236 and m/z 99). The scan width 
was 0.4 m/z and the scan time was 0.08 seconds. Q1 and Q3 resolution was 0.70 FWHM. 
Limits of quantitation were as follows: 1: 0.6 pmol/mL urine, 2 as [2H3]4: 0.4 pmol/mL 
urine; 3 as [2H3]5: 0.7 pmol/mL urine; 4: 0.2 pmol/mL urine; 5: 0.7 pmol/mL urine. Urinary 
metabolite levels were standardized to creatinine levels in the urine for each sample.
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High resolution analysis was performed on a Thermo Scientific Orbitrap Velos using the 
same transitions as above with a product scan from m/z 50–300. The LC conditions were 
identical to the selected reaction monitoring assay.
Precision
Precision was measured by repeatedly processing pooled smoker urine at the same time as 
other samples and determining the standard deviation of the metabolite levels. A total of 
eight pooled smoker urine samples were measured on separate days. The coefficient of 
variation (CV) for precision of detection was 8–31% for the three analytes of interest (Table 
S1).
Statistical Analysis
Smoker versus non-smoker values were compared using a two tailed Student’s t-test. 
Cessation values were evaluated for significant changes using ANOVA followed by post-hoc 
t-tests. Correlations between metabolite 3 and previously measured tobacco biomarkers24 at 
the baseline were assessed using the Pearson’s product moment correlation coefficient, and 
significance was assessed for 2-sided alternatives under 5% level of significance. The 
tobacco constituent biomarkers were: cigarettes smoked per day, cotinine, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), 1-hydroxypyrene (HOP), 2-
hydroxyethyl mercapturic acid (HEMA), 1-(N-acetylcysteinyl)-2-hydroxy-3-butene 
(MHBMA), 1,2-dihydroxy-4-(N-acetylcysteinyl)butane (DHBMA), 1-(N-acetylcysteinyl)-
propan-3-ol (HPMA), 2-(N-acetylcysteinyl)butan-4-ol (HMPMA), and (N-
acetylcysteinyl)benzene (SPMA).
To assess whether the changes in metabolite 3 levels are significant over time, linear 
regression based on (normal) generalized estimating equations (GEE) was used, controlling 
for the repeated measures for each study subject and with an initial correlation matrix that is 
autoregressive with order one.28
Results
We had previously reported sensitive negative ion LC-MS/MS methods for the quantification 
of metabolites 1 and 4 in microsomes and hepatocytes.16,17 Metabolite 1 was detected by 
following the neutral loss of 42 amu (m/z 253 → m/z 211) whereas metabolite 4 was 
detected by monitoring the neutral loss of 129 (m/z 398 → m/z 269). Application of these 
methods to urine required more extensive sample clean up prior to the mass spectral analysis 
so we adapted a published method for the detection of urinary mercapturic acid metabolites 
of tobacco smoke constituents for our purposes.24 Preliminary studies indicated that there 
were significant contaminants that interfered with the detection of metabolite 2 when the 
neutral loss of 129 amu was monitored for this metabolite (m/z 356 → m/z 227). Therefore, 
the samples were treated with [2H6]acetic anhydride to convert metabolite 2 to [2H3]4 
(Scheme 2). The selected reaction of m/z 401 to m/z 272 monitored for this derivatized 
metabolite yielded a chromatogram that had reduced background and fewer peaks that 
interfered with its detection. Conversion was considered to be close to 100% as judged by 
the absence of un-derivatized 2 in the urine samples treated with acetic anhydride. 
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Reproducibility was judged by spiking pooled smokers urine with 0–24 nmol of a mixture of 
2 and 4 prior to treatment with [2H6]acetic anhydride. The ratio of [2H3]4 to 4 was 1.5 ± 0.2 
(n=4) in these samples after subtracting out the contribution from the pre-existing 
metabolites, indicating that the conversion of 2 to [2H3]4 was reproducible. The 
[2H3]acetylation reaction also resulted in the conversion of the BDA-lysine reaction product 
6 (Scheme 1) to [2H3]1 and metabolite 3 to [2H3]5 (Scheme 2). Following acetylation, urine 
was subjected to a two-step solid phase extraction process using sequential mixed mode 
anion exchange and reverse phase cartridges (Scheme 2). Two fractions were collected from 
the ion exchange cartridge. The first fraction which was eluted with 40% (v/v) methanol 
contained 1, 6 (as [2H3]1), 3 (as [2H3]5) and 5. The second, less polar, fraction eluted with 
100% methanol contained 2 (as [2H3]4) and 4. The two fractions were then concentrated and 
applied to C18 cartridges for an additional purification step. The fractions were dried and 
reconstituted in the LC mobile phase prior to LC-MS/MS analysis.
Urinary furan metabolites were initially identified by spiking the urine samples with stable 
isotopically labeled forms of the metabolites, [13C615N2]1, [13C615N2]2, [13C615N2]4, and 
[13C615N2]5 and investigating whether there were unlabeled forms of the metabolites in the 
urine samples that co-eluted with the internal standards. The specific mass spectral 
transitions monitored are outlined in Scheme 2. Representative mass chromatograms 
obtained for a urine sample from a human smoker are displayed in Figure 1. This sample 
was typical for most of the human urine samples; metabolites 1, 2 and 3 were detected 
whereas metabolite 4 and 5 were below the limits of detection (Table 1). Some samples 
contained metabolite 4 whereas metabolite 5 was at or below the limits of detection in most 
individuals. Metabolite 6 as [2H3]1 was identified in a subset of samples re-analyzed 
specifically looking for this metabolite.
The identities of the human metabolites 1, 2 and 3 were further confirmed with high 
resolution LC-MS/MS. All three metabolites had the same mass within 5 ppm as the 
chemically prepared standards. The mass spectrum of metabolite 1 displayed ions at m/z 
82.0306, 128.0723 and 211.109 similar to synthetic 1 (Figure S1). Metabolite 2 (as [2H3]4) 
had fragments at m/z 98.00768 and 288.0960, the latter fragment was shifted by 1 amu due 
to the deuterium substitution on the acetyl group (Figure S2). The mass spectrum of 
metabolite 3, as [2H3]5 contained three fragments at m/z 114.00272, 244.0877 and 
288.11014 (Figure S3); the latter two fragments were shifted by 1 and 3 amu, respectively, 
as a result of deuterium substitution on the acetyl group.
The metabolites were quantified by comparing the peak area of the analyte to that of the 
internal standard. Quantification of these metabolites in human urine indicated that BDA-
lysine metabolite 1 was the most abundant metabolite in all samples (Table 1). In the POB 
study, the relative levels were: 1 > sulfoxide 3 > sulfide 2. In the Asian cohorts, the relative 
levels were BDA-N-acetyl-lysine metabolite 1 > sulfide 2 and sulfoxide 3. The relative 
levels of 2 and 3 depended on the individuals in this group with sulfide 2 was greater than 
sulfoxide 3 in some individuals and 3 was more abundant than 2 in others. The relative 
levels of these two metabolites were not dependent on smoking status.
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In the Minnesota group (POB study), there was some difficulty quantifying metabolites 1 
and 2. Co-elution of impurities with [13C615N2]1 and metabolite 2 affected their quantitation 
in numerous samples, leading to an underestimation of metabolite 1 in many smokers and an 
overestimation of metabolite 2 in many nonsmokers. These interfering peaks were present in 
only a couple of the samples from the Shanghai and Singapore cohorts.
Urinary levels of sulfoxide 3 were elevated in smokers as compared to non-smokers in all 
three cohorts (Figures 2A and 3 and Table 1). Levels of the lysine metabolites 6 (measured 
as [2H3]1) and 1 were also elevated in smokers relative to non-smokers in the Singapore and 
Shanghai cohort samples (Figure 3 and Table 1). In the POB study, urine samples were 
collected at various time points following smoking cessation. Consistent with the association 
of sulfoxide 3 levels with smoking in this group, the levels of this metabolite decreased 
significantly following smoking cessation (p-value < 0.0001, Figure 2B). After three days, 
the levels were significantly lower when compared to baseline levels (p-value < 0.0003) with 
continual decrease thereafter. While the levels of metabolite 3 reached a minimum after 28 
days of cessation, they were still significantly higher as compared to non-smokers even after 
84 day cessation (p-value < 0.005). Unfortunately, metabolite 1 could not be followed in 
these cessation samples due to the presence of interfering peaks.
To explore whether baseline levels of metabolite 3 are correlated to other biomarkers of 
tobacco smoke constituents, we compared the levels of this compound to those previously 
reported in smokers of the POB study (Figure S4).24 Levels of metabolite 3 were correlated 
to the number of cigarettes smoked per day (ρ = 0.464, p-value = 0.081), but the correlation 
coefficient was not statistically significant due to the small sample size. They were 
significantly correlated with several tobacco specific biomarkers such as urinary cotinine 
levels (ρ = 0.618, p-value = 0.014), a metabolite of nicotine and NNAL (ρ = 0.657, p-value 
= 0.007), a metabolite of the lung specific carcinogen, 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK).29–31 HPMA and HMPMA are the biomarkers of exposure to 
acrolein and crotonaldehyde, respectively. These two α, β-unsaturated aldehydes have been 
previously quantified in cigarette smoke.32,33 Levels of metabolite 3 are significantly 
associated with both HPMA (ρ = 0.631, p-value = 0.011) and HMPMA (ρ = 0.615, p-value 
= 0.014). Borderline associations were observed for two other metabolites of tobacco smoke 
chemicals, pyrene and ethylene oxide (HOP:ρ = 0.513, p-value = 0.05 and HEMA: ρ = 
0.48, p-value = 0.07, respectively).32,34 There was no statistically significant correlation 
coefficients with the mercapturic acid metabolites of 1,3-butadiene (MHBMA and DHBMA, 
ρ = 0.349 and 0.392, respectively) or benzene (SPMA, ρ = 0.158). Like furan, 1,3-butadiene 
and benzene are substrates for cytochrome P450 2E1.16,35,36
In urine from furan-treated rats and mice, metabolites 1 – 5, but not 6 (as [2H3]1), were 
observed (Table 2). The relative amounts of these metabolites differed between rats and 
mice. In rat urine, the lysine reaction product 1 was the most abundant metabolite detected 
by this quantitative method. The relative amounts of the metabolites derived from cysteine-
BDA-lysine cross-links was sulfoxide 5 > sulfide 2 ≅ sulfoxide 4 > sulfide 3 with the sum of 
these four metabolites less than the levels of the BDA-lysine derived metabolite, 1. There 
was a roughly ten-fold increase in all the metabolites at the higher dose with no significant 
change in the relative distribution of each metabolite. In the mouse, the most abundant 
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metabolite detected was the N-acetylcysteine-BDA-lysine cross-link 2. Its sulfoxide 3 was 
next most abundant followed by the BDA-N-acetyllysine metabolite 1. Lysine acetylation of 
the N-acetylcysteine-BDA-lysine cross-link 2 was a minor pathway in this species.
Discussion
Previous studies in rats indicated that abundant urinary metabolites of furan were derived 
from the reaction of BDA with lysine and cysteine.3,4,6 Metabolites 1 and 6 are products of 
the reaction of BDA with lysine whereas metabolites 2 – 5 are derived from the crosslinking 
of cysteine to lysine by this reactive compound. In this report, five of these six furan 
metabolites were detected in urine of furan-treated rodents (metabolites 1 – 5) and four were 
detected in most human urine samples (metabolites 1, 2, 3 and 6).
While the cysteine-BDA-lysine derived metabolites, sulfide 4 and sulfoxide 5 were 
identified as major furan metabolites in rat urine using non-quantitative mass spectrometry 
methods,4,6 the quantitative assay presented in this report indicates that the BDA-lysine 
metabolite 1 is actually more abundant than both the sulfide 4 and sulfoxide 5 (Table 2). 
Similarly, metabolite 2 was thought to be a minor metabolite,4 but this current report 
demonstrates that metabolites 2 and 4 are present in comparable amounts in rat urine. The 
total sum of cysteine-BDA-lysine derived metabolites (2 – 5) was less than the BDA-lysine 
metabolite 1. This finding was somewhat surprising given that studies in rat hepatocytes 
indicated that the formation of glutathione-BDA-lysine metabolites occurred to a much 
greater extent than metabolite 1;3,17 glutathione-BDA-lysine is likely a major precursor to 
metabolites 2 – 5.3,17 A likely explanation for this discrepancy is that we are not accounting 
for all of the cysteine-BDA-lysine-derived metabolites reported in rat urine. The cysteine 
derivative can be metabolized by sequentially by β-lysase, S-methyltransferase and sulfur 
oxidases, respectively, whereas the lysine residue can undergo oxidative deamination.4 The 
latter pathway is reported to be significant in rats.4,6 Consequently, not all the metabolites 
derived from the cross-link are accounted for in this current study. Future studies will 
involve the development of quantitative methods for these additional metabolites.
Furan-derived metabolites have not been previously reported in mice. In this species, the 
cysteine-BDA-lysine derived sulfide 2 is more abundant than the BDA-lysine reaction 
product 1, suggesting that cysteine-BDA-lysine cross-link formation is more abundant than 
direct BDA-lysine adduct formation (Table 2). This is consistent with our previous 
observations of the relative formation of metabolite 1 and glutathione-BDA-lysine in mouse 
hepatocytes.17 The higher levels of metabolites 2 and 3 in the urine of mice relative to rats 
indicate that the cysteine and lysine residues of the cross-link are less susceptible to further 
metabolism in mice. Analysis by ion trap mass spectrometry indicated that the metabolic 
profile of furan metabolites in mice was much simpler than that observed for rats and there 
was little evidence of any further metabolism of the cysteine and lysine portions of this 
cross-link beyond acetylation of the lysine residue and S-oxidation (data not shown). The 
absence of these compounds will be confirmed in future studies in which quantitative 
methods for the other rat metabolites are employed.
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Furan metabolites 1, sulfide 2 and sulfoxide 3 were detected in all but two of the human 
samples; significantly lower levels of sulfide 4 and sulfoxide 5 were detected in only some 
human samples. Unlike rodents, the non-acetylated BDA-lysine metabolite 6 was also 
present. The acetylated BDA-lysine compound 1 was the most abundant furan metabolite 
detected in the human samples, consistent with the observation that this direct reaction 
product was the dominant BDA-derived metabolite of furan in human hepatocytes.17 The 
sulfoxide metabolite 3 was the second most abundant BDA-derived reaction product 
detected in most of the human samples; however, sulfide 2 was more abundant than the 
sulfoxide 3 in some of the samples. The latter case occurred more frequently in the Asian 
cohort samples and was not associated with smoking status.
The observation that the sulfoxide 3 was more abundant than the corresponding mercapturic 
acid in all of the POB samples and more than half of the Asian co-hort samples is a novel 
finding. While mercapturic acid sulfoxides have been reported for a number of compounds 
in rodent urine,3,37,38 most human urinary biomarker studies focus on the mercapturic acid 
metabolites of environmental chemicals.24,39,40 The oxidation of the mercapturic acid 2 to 
the sulfoxide 3 likely results from an enzyme-mediated process since the ratio of the two 
diastereomers was ~11/1 (R/S; Figure S5). This average ratio remained constant regardless 
of smoking status. This contrasts with approximately equal amounts of the diastereomers 
formed when 2 undergoes chemical oxidation to 3.3 This evidence supports the hypothesis 
that the sulfoxide 3 detected in urine is formed enzymatically and not as a result of air 
oxidation. Cytochrome P450 and flavin-containing monooxygenase (FMO) are two enzymes 
capable of oxidizing mercapturic acids to their sulfoxides, with CYP3A enzymes being the 
most active.41–43
Levels of metabolite 3 were related to smoking in all three groups. Smoking associations 
were also observed for metabolites 1 and 6 in the Asian groups (Figures 2 and 3). 
Unfortunately, the measurement of 1 was confounded in the Minnesota study due to co-
eluting contaminants with the internal standard, likely underestimating the levels of this 
metabolite in many smokers. Urinary levels of metabolite 3 dropped gradually following 
smoking cessation. This decline differed from the immediate drop observed for the 
mercapturic acid derivatives of other tobacco smoke chemicals such as benzene, butadiene 
and acrolein.24 This behavior is consistent with the expectation that 3 is derived from the 
degradation of BDA-modified proteins3 which would result in a gradual decline in urinary 
levels over time.
The abundance of furan in tobacco smoke supports furan as the precursor to metabolites 1, 3 
and 6 in smoker’s urine.12–14 However, other sources cannot be excluded since there are 
other potential sources of BDA. First, BDA itself may be a component of tobacco smoke. 
This question has not been examined but other α,β-unsaturated aldehydes have been 
detected in tobacco smoke.32,33 Second, metabolite 3 or its precursor could be a metabolite 
of other tobacco constituents. Finally, BDA may be endogenously generated by radicals and 
reactive oxygen species-generating chemicals;44–46 both of which are abundant in cigarette 
smoke. Radical reactions with DNA generate the trans-isomer of BDA47 and BDA has been 
proposed to be a product of lipid peroxidation.48 Acrolein and crotonaldehyde are also both 
present in tobacco smoke and are formed as a consequence of lipid peroxidation.32,33,49 
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These compounds are both α,β-unsaturated aldehydes like BDA. It is interesting to note that 
their metabolites, HPMA and HMPMA, are correlated with metabolite 3 in the POB study 
samples. Further studies need to be conducted to clarify all the possible sources of BDA that 
result from tobacco smoking.
Tobacco smoke is not the only possible source of these metabolites. Humans are also 
exposed to furan through processed food, pollution, car exhaust and wood smoke.8,9 Future 
studies will examine the relative contribution of these exposures to the levels of these 
metabolites in non-smokers.
It is worth noting that the levels of metabolites 1, 2 and 3 were generally similar among the 
three human studies. The Shanghai and Singapore cohort specimens are more than 25 years 
old suggesting that the metabolites are stable with storage. In addition, the difference 
between smokers and nonsmokers was maintained over this period of time. This indicates 
that the preparatory and analysis methods described in this report could be applied to 
numerous existing studies to determine if there is adverse health effects associated with this 
exposure.
In summary, a sensitive LC-MS/MS assay was employed to detect potential furan 
metabolites in human urine. Several of these metabolites, 1, 3 and 6 were associated with 
smoking in humans, and therefore should also be explored as potential biomarkers of 
exposure to BDA and, possibly furan. Future studies will be performed with these 
biomarkers to determine if their levels are associated with adverse health effects associated 
with exposure to mixtures containing furan such as tobacco smoke.
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Representative LC-MS/MS chromatograms of a urine sample from a smoker. A) Metabolite 
1; B) metabolites 3 (as [2H3]5) and 5; C) metabolite 2 (as [2H3]4); and D) metabolite 4. 
Peaks of interest are highlighted.
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Urinary levels of metabolite 3 in A) non-smokers and smokers and B) before and after 
cessation. Data is presented as average urinary level normalized to creatinine ± S.D. 
*Metabolite 3 was significantly higher in smokers versus nonsmokers as determined by a 
Student t-test, p-value < 1 × 10−7. **Levels of 3 significantly dropped in smokers after 
cessation as determined by ANOVA followed by post-hoc Student t-test, p-value < 0.005.
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Urinary levels of furan metabolites in non-smokers and smokers from the Shanghai and 
Singapore cohorts: A) metabolite 6, B) metabolite 1 and C) metabolite 3. Data is presented 
as average urinary level normalized to creatinine ± S.D. These metabolites were significantly 
higher in smokers versus nonsmokers as determined by a Student t-test. *p-value < 0.01. ** 
p-value < 0.001.
Grill et al. Page 17














Formation of urinary furan metabolites.
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Preparation of human urine for LC-MS/MS analysis.
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